Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price

Rituximab Biosimilars Market 2021 - By Application (Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Mail Orders) And By Region, Opportunities And Strategies – Global Forecast To 2030

Rituximab Biosimilars Global Market Opportunities And Strategies To 2030: COVID 19 Growth And Change

Starting Price : $4000.00 | Pages : 229 | Published : May 2021 | | Format : pdf

Purchase Options
Request Sample
Request For Discount
Customise Your Report
Request For Proposal
Request For Regional Data

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Rituximab Biosimilars Market Definition

The rituximab biosimilars market consists of sales of rituximab biosimilars and related services used to treat chronic diseases such as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), microscopic polyangiitis (MPA), and granulomatosis with polyangiitis (GPA).

Biosimilars are biological products produced to be identical to a biologic already approved, known as reference drugs. Biosimilars are expected to have similar safety and efficacy compared to the reference biologic product. The rituximab biosimilars market comprises of sales of only rituximab biosimilars, for the treatment of autoimmune diseases.

Rituximab Biosimilars Market Size

The rituximab biosimilar market reached a value of nearly $1,602.1 million in 2020, having increased at a compound annual growth rate (CAGR) of 67.9% since 2015. The market is expected to grow from $1,602.1 million in 2020 to $3,474.2 million in 2025 at a rate of 16.7%. The market is then expected to grow at a CAGR of 10.5% from 2025 and reach $5,723.6 million in 2030.  

Growth in the historic period resulted from government initiatives, increased healthcare expenditure, increase in biopharmaceutical R&D expenditure, low cost of biosimilars, and emerging markets growth. Factor that negatively affected growth in the historic period was effect of Covid-19, low number of drug approvals, and lack of awareness on biosimilars among primary care physicians and specialists.

Going forward, aging population, increase in healthcare access, and rising prevalence of chronic diseases, will drive the growth. Factors that could hinder the growth of the rituximab biosimilar market in the future include stringent regulations related to biosimilar approvals, and prolonged production and approval time.

Rituximab Biosimilars Market Drivers

The key drivers of the rituximab biosimilars market include:

Aging Population

The population profile of most countries is becoming older, thus driving the demand for diagnosing and treating various diseases including cancer. The proportion of people above the age of 65 years increased globally and age-related chronic ailments also increased. For example, the percentage of seniors is expected to grow from 28% in 2019 to 38% in 2050 in Japan. The increase in the aging population has increased the patient pool of many chronic diseases such as cancer. People suffering from these diseases are expected to be more vulnerable to chronic diseases, thus significantly impacting market growth during this period.

Rituximab Biosimilars Market Restraints

The key restraints on the rituximab biosimilars market include:

Stringent Regulations Related To Biosimilar Approvals

Stringent regulations imposed on approvals of biosimilars is anticipated to hinder the growth of the rituximab biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics, whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. In February 2019, out of the total 17 approved biosimilars, only 7 biosimilars including 4 originating biologics could enter the US commercial market. The robust government policies for approval of these drugs negatively impact manufacturers in the rituximab biosimilar market.

Rituximab Biosimilars Market Trends

Major trends influencing the rituximab biosimilars market include:

Revised FDA Regulations To Facilitate Biosimilar Drug Development

The US Food and Drug Administration (FDA) has revised its regulations to eliminate outdated biologics and biosimilar requirements, thus allowing drug manufacturers to employ new manufacturing technologies and testing capabilities. Standard preparations (standard solutions containing a precisely known concentration of an element), which help to ensure safety, purity and potency of biologics/biosimilar, can now be obtained from sources other than the FDA’s Center for Biologics Evaluation and Research (CBER), or can be developed internally by the biologics license applicant. The FDA has also removed a rule (Section 610.21 of FDA code) which specifies minimal potency limits to be met for certain antibodies and antigens. In addition, the FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. These amendments in regulations are expected to increase regulatory flexibility by allowing the pharmaceutical industry and the FDA to incorporate current scientific technologies in the manufacture of licensed biological products.

The average yearly number of new drug approvals was 25 between 2000 and 2009, and 41 between 2010 and 2018. The new biologic product approvals increased from a median of 5 between 2000 and 2013, to 12 between 2014 and 2018. Also, by mid- November 2020, 42 new medicines and biologics got approved by FDA and EMA.

Large Number Of Strategic Partnerships and Collaborations.

Companies in the rituximab biosimilar market are increasing their product innovation and marketing activities through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in- or out-licensing deals, this trend has been increasing over recent years. For instance, In October 2019, iBio, Inc., Delware-based biotechnology company involved in development of vaccine and therapeutics expanded its strategic partnership/collaboration with CC-Pharming, a Beijing-based company specialized in biological R&D for development of rituximab biosimilar in China. In October 2019, Celltrion Healthcare, a subsidiary of South Korea-based biopharmaceutical company Celltrion entered into co-marketing agreement with Juno Pharmaceuticals, an Australian supplier of medical and pharmaceutical products, to market its biosimilar products Herzuma, Truxima  (biosimilar rituximab) in Australia.  

Opportunities And Recommendations In The Rituximab Biosimilars Market

Opportunities –The top opportunities in the rituximab biosimilar market segmented by application will arise in the non-hodgkin’s lymphoma segment, which will gain $565.9 million of global annual sales by 2025. The top opportunities in segment by distribution channel will arise in the hospital pharmacy segment, which will gain $1,302.3 million of global annual sales by 2025. The rituximab biosimilar market size will gain the most in the USA at $896.2 million.

Recommendations-To take advantage of these opportunities, The Business Research Company recommends the rituximab biosimilars manufacturing companies to consider investing in the development of the new rituximab biosimilars, work on strategic alliances for research & development to speed-up the drug discovery and manufacturing process, expanding activities to the European Unions and other emerging markets to gain market share, offer competitively priced and cost effective drugs to attract the users, leverage online pharmacies and business websites to reach targeted physicians and customers, among other strategies.

Rituximab Biosimilars Market Segmentation

The rituximab biosimilars market is segmented by application, by distribution channel and by geography.
By Application -
The rituximab biosimilars market is segmented by application into
    • a) Non-Hodgkin’s Lymphoma
    • b) Chronic Lymphocytic Leukemia
    • c) Rheumatoid Arthritis
    • d) Others
The rituximab biosimilar market is segmented by application into non-hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and others. The non-hodgkin’s lymphoma was the largest segment of the rituximab biosimilar market segmented by application, accounting for 28.5% of the total in 2020. Going forward, the rheumatoid arthritis segment is expected to be the fastest growing segment in the rituximab biosimilar market segmented by application, at a CAGR of 18.3% during 2020-2025.
By Distribution Channel-
The rituximab biosimilars market is further segmented by distribution channel into
    • a) Retail Pharmacies
    • b) Hospital Pharmacies
    • c) Mail Orders
The rituximab biosimilar market is also segmented by distribution channel into hospital pharmacy, mail order and retail pharmacy. The hospital pharmacy was the largest segment of the rituximab biosimilar market segmented by distribution channel, accounting for 87.7% of the total in 2020. Going forward, the mail order segment is expected to be the fastest growing segment in the rituximab biosimilar market segmented by distribution channel, at a CAGR of 34.0% during 2020-2025.
By Geography-
The rituximab biosimilars market is segmented by geography into
    • o North America
      • • USA
      • o Western Europe
      • • UK
      • • Germany
      • • France
      o Asia Pacific
      • • China
      • • Japan
      • • India
      • • Australia
      • • Indonesia
      • • South Korea
      o Eastern Europe
      • • Russia
      o South America
      • • Brazil
      o Middle East
      o Africa
North America was the largest region in the rituximab biosimilar market, accounting for 48.0% of the total in 2020. It was followed by Western Europe and Eastern Europe, and then the other regions. Going forward, the fastest-growing regions in the rituximab biosimilar market will be South America, and Asia Pacific, where growth will be at CAGRs of 36.7% and 29.2% respectively. These will be followed by North America, and Western Europe where the markets are expected to grow at CAGRs of 18.3% and 13.6% respectively.

Rituximab Biosimilars Competitive Landscape

Major Competitors In The Rituximab Biosimilars Market are:

  • Teva/Cellitron
  • Novartis AG
  • Pfizer
  • BIOCAD
  • Shanghai Henlius Biotech, Inc.

    • Other Competitors In The Rituximab Biosimilars Market Include:

  • Hikma Pharmaceuticals plc
  • Sandoz (Novartis)
  • Aryogen Biopharma
  • TR-Pharm
  • Dr. Reddy’s Laboratories Ltd
  • Celltrion Healthcare
  • mAbxience
  • Janssen Pharmaceutical
  • Amgen
  • Teva Pharmaceuticals
  • Celltrion Healthcare
  • Coherus BioSciences
  • Innovent Biologics
  • Mylan
  • MABION S.A
  • NAPP Pharmaceuticals Limited
  • Novartis (Sandoz)
  • Mundipharma Deutschland GmbH & Co. KG
  • Shanghai Henlius Biotech
  • Innovent Biologics, Inc.
  • Sinocelltech
  • Cadila Pharmaceuticals
  • Hetero Drugs Limited
  • Shanghai Fosun Pharmaceutical(Group)Co., Ltd.
  • Reliance Life Sciences, India
  • Zenotech Laboratories

      • Table Of Contents

      1. Rituximab Biosimilars Market Executive Summary

      2. Table of Contents

      3. List of Figures

      4. List of Tables

      5. Report Structure

      6. Introduction

      6.1.1. Segmentation By Geography

      6.1.2. Segmentation By Application

      6.1.3. Segmentation By Distribution Channel

      7. Rituximab Biosimilars Market Characteristics

      7.1. Market Definition

      7.2. Market Segmentation By Application

      7.2.1. Non-Hodgkin’s Lymphoma

      7.2.2. Chronic Lymphocytic Leukemia

      7.2.3. Rheumatoid Arthritis

      7.2.4. Others

      7.3. Market Segmentation By Distribution Channel

      7.3.1. Retail Pharmacy

      7.3.2. Hospital Pharmacy

      7.3.3. Mail Order

      8. Rituximab Biosimilars Market Trends And Strategies

      8.1. Revised FDA Regulations To Facilitate Biosimilar Drug Development

      8.2. Large Number Of Strategic Partnerships and Collaborations.

      8.3. Robust Research & Development

      9. Impact Of COVID-19 On The Rituximab Biosimilars Market

      9.1. Impact On The Global Rituximab Biosimilars Market

      9.2. How Leading Rituximab Biosimilars Companies Handled COVID

      10. Global Rituximab Biosimilars Market Size And Growth

      10.1. Market Size

      10.2. Historic Market Growth, 2015 – 2020, Value ($ Million)

      10.2.1. Drivers Of The Market 2015 – 2020

      10.2.2. Restraints On The Market 2015 – 2020

      10.3. Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      10.3.1. Drivers Of The Market 2020 – 2025

      10.3.2. Restraints On The Market 2020 – 2025

      11. Global Rituximab Biosimilars Market Segmentation

      11.1. Global Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      11.1.1. Non-Hodgkin’s Lymphoma

      11.1.2. Chronic Lymphocytic Leukemia

      11.1.3. Rheumatoid Arthritis

      11.1.4. Others

      11.2. Global Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      11.2.1. Hospital Pharmacy

      11.2.2. Retail Pharmacies

      11.2.3. Mail Order

      12. Rituximab Biosimilars Market, Regional And Country Analysis

      12.1. Global Rituximab Biosimilars Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      12.2. Global Rituximab Biosimilars Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13. Asia-Pacific Rituximab Biosimilars Market

      13.1. Asia-Pacific Rituximab Biosimilars Market Overview

      13.1.1. Region Information

      13.1.2. Market Information

      13.1.3. COVID-19 Impact

      13.1.4. Background Information

      13.1.5. Government Initiatives

      13.1.6. Regulations

      13.1.7. Regulatory Bodies

      13.1.8. Major Associations

      13.1.9. Taxes Levied

      13.1.10. Corporate Tax Structure

      13.1.11. Investments

      13.1.12. Major Companies

      13.2. Asia-Pacific Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.3. Asia-Pacific Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.4. Asia-Pacific Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.5. Asia-Pacific Rituximab Biosimilars Market: Country Analysis

      13.6. China Rituximab Biosimilars Market

      13.7. China Rituximab Biosimilars Market Overview

      13.8. China Rituximab Biosimilars Market Overview

      13.8.1. Country Information

      13.8.2. Market Information

      13.8.3. COVID-19 Impact

      13.8.4. Background information

      13.8.5. Government Initiatives

      13.8.6. Regulations

      13.8.7. Regulatory Bodies

      13.8.8. Major Associations

      13.8.9. Taxes levied

      13.8.10. Corporate tax structure

      13.8.11. Investments

      13.8.12. Major Companies

      13.9. China Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.10. China Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.11. China Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.12. India Rituximab Biosimilars Market

      13.13. India Rituximab Biosimilars Market Overview

      13.13.1. Country Information

      13.13.2. Market Information

      13.13.3. COVID-19 Impact

      13.13.4. Background Information

      13.13.5. Government Initiatives

      13.13.6. Regulations

      13.13.7. Regulatory Bodies

      13.13.8. Major Associations

      13.13.9. Taxes Levied

      13.13.10. Corporate Tax Structure

      13.13.11. Investments

      13.13.12. Major Companies

      13.14. India Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.15. India Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.16. India Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.17. Japan Rituximab Biosimilars Market

      13.18. Japan Rituximab Biosimilars Market Overview

      13.18.1. Country Information

      13.18.2. Market Information

      13.18.3. COVID-19 Impact

      13.18.4. Background Information

      13.18.5. Government Initiatives

      13.18.6. Regulations

      13.18.7. Regulatory Bodies

      13.18.8. Major Associations

      13.18.9. Taxes Levied

      13.18.10. Corporate Tax Structure

      13.18.11. Investments

      13.18.12. Major Companies

      13.19. Japan Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.20. Japan Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.21. Japan Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.22. Australia Rituximab Biosimilars Market

      13.23. Australia Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.24. Australia Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.25. Australia Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.26. Indonesia Rituximab Biosimilars Market

      13.27. Indonesia Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.28. Indonesia Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.29. South Korea Rituximab Biosimilars Market

      13.30. South Korea Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.31. South Korea Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.32. South Korea Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      14. Western Europe Rituximab Biosimilars Market

      14.1. Western Europe Rituximab Biosimilars Market Overview

      14.1.1. Region Information

      14.1.2. Market Information

      14.1.3. COVID-19 Impact

      14.1.4. Background Information

      14.1.5. Government Initiatives

      14.1.6. Regulations

      14.1.7. Regulatory Bodies

      14.1.8. Major Associations

      14.1.9. Taxes Levied

      14.1.10. Corporate Tax Structure

      14.1.11. Investments

      14.1.12. Major Companies

      14.2. Western Europe Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      14.3. Western Europe Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      14.4. Western Europe Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      14.5. Western Europe Rituximab Biosimilars Market: Country Analysis

      14.6. UK Rituximab Biosimilars Market

      14.7. UK Rituximab Biosimilars Market Overview

      14.7.1. Country Information

      14.7.2. Market Information

      14.7.3. COVID-19 Impact

      14.7.4. Background Information

      14.7.5. Government Initiatives

      14.7.6. Regulations

      14.7.7. Regulatory Bodies

      14.7.8. Major Associations

      14.7.9. Taxes Levied

      14.7.10. Corporate Tax Structure

      14.7.11. Investments

      14.7.12. Major Companies

      14.8. UK Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      14.9. UK Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      14.10. UK Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      14.11. Germany Rituximab Biosimilars Market

      14.12. Germany Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      14.13. Germany Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      14.14. Germany Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      14.15. France Rituximab Biosimilars Market

      14.16. France Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      14.17. France Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      14.18. France Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      15. Eastern Europe Rituximab Biosimilars Market

      15.1. Eastern Europe Rituximab Biosimilars Market Overview

      15.1.1. Region Information

      15.1.2. Market Information

      15.1.3. COVID-19 Impact

      15.1.4. Background Information

      15.1.5. Government Initiatives

      15.1.6. Regulations

      15.1.7. Regulatory Bodies

      15.1.8. Associations

      15.1.9. Taxes levied

      15.1.10. Corporate Tax Structure

      15.1.11. Investment

      15.1.12. Major Companies

      15.2. Eastern Europe Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      15.3. Eastern Europe Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      15.4. Eastern Europe Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      15.5. Eastern Europe Rituximab Biosimilars Market: Country Analysis

      15.6. Russia Rituximab Biosimilars Market

      15.7. Russia Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      15.8. Russia Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      15.9. Russia Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      16. North America Rituximab Biosimilars Market

      16.1. North America Rituximab Biosimilars Market Overview

      16.1.1. Region Information

      16.1.2. Market Information

      16.1.3. COVID 19 Impact

      16.1.4. Background Information

      16.1.5. Government Initiatives

      16.1.6. Regulations

      16.1.7. Regulatory Bodies

      16.1.8. Major Associations

      16.1.9. Taxes Levied

      16.1.10. Corporate Tax Structure

      16.1.11. Investments

      16.1.12. Major Companies

      16.2. North America Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      16.3. North America Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      16.4. North America Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      16.5. North America Rituximab Biosimilars Market: Country Analysis

      16.6. USA Rituximab Biosimilars Market

      16.7. USA Rituximab Biosimilars Market Overview

      16.7.1. Country Information

      16.7.2. Market Information

      16.7.3. COVID 19 Impact

      16.7.4. Background Information

      16.7.5. Government Initiatives

      16.7.6. Regulations

      16.7.7. Regulatory Bodies

      16.7.8. Major Associations

      16.7.9. Tax Levied

      16.7.10. Corporate Tax Structure

      16.7.11. Investments

      16.7.12. Major Companies

      16.8. USA Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      16.9. USA Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      16.10. USA Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      17. South America Rituximab Biosimilars Market

      17.1. South America Rituximab Biosimilars Market Overview

      17.1.1. Region Information

      17.1.2. Market Information

      17.1.3. COVID-19 Impact

      17.1.4. Background Information

      17.1.5. Government Initiatives

      17.1.6. Regulations

      17.1.7. Regulatory Bodies

      17.1.8. Major Associations

      17.1.9. Taxes levied

      17.1.10. Corporate Tax Structure

      17.1.11. Investments

      17.1.12. Major Companies

      17.2. South America Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      17.3. South America Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      17.4. South America Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      17.5. South America Rituximab Biosimilars Market: Country Analysis

      17.6. Brazil Rituximab Biosimilars Market

      17.7. Brazil Rituximab Biosimilars Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      17.8. Brazil Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      17.9. Brazil Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      18. Middle East Rituximab Biosimilars Market

      18.1. Middle East Rituximab Biosimilars Market Overview

      18.1.1. Region Information

      18.1.2. COVID 19 impact

      18.1.3. Background Information

      18.1.4. Government Initiatives

      18.1.5. Regulations

      18.1.6. Regulatory Bodies

      18.1.7. Major Associations

      18.1.8. Taxes Levied

      18.1.9. Corporate Tax Structure

      18.1.10. Investments

      18.1.11. Major Companies

      18.2. Middle East Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      18.3. Middle East Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      19. Africa Rituximab Biosimilars Market

      19.1. Africa Rituximab Biosimilars Market Overview

      19.1.1. Region Information

      19.1.2. COVID-19 impact

      19.1.3. Background Information

      19.1.4. Government Initiatives

      19.1.5. Regulations

      19.1.6. Regulatory Bodies

      19.1.7. Associations

      19.1.8. Taxes levied

      19.1.9. Corporate Tax Structure

      19.1.10. Investments

      19.1.11. Major Companies

      19.2. Africa Rituximab Biosimilars Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      19.3. Africa Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      20. Global Rituximab Biosimilars Market Competitive Landscape

      20.1. Company Profiles

      20.2. Teva Pharmaceuticals

      20.2.1. Company Overview

      20.2.2. Products And Services

      20.2.3. Business Strategy

      20.2.4. Financial Overview

      20.3. Novartis AG

      20.3.1. Company Overview

      20.3.2. Products And Services

      20.3.3. Financial Overview

      20.4. Pfizer

      20.4.1. Company Overview

      20.4.2. Products And Services

      20.4.3. Business Strategy

      20.4.4. Financial overview

      20.5. BIOCAD

      20.5.1. Company Overview

      20.5.2. Products And Services

      20.5.3. Business Strategy

      20.5.4. Financial Overview

      20.6. Shanghai Henlius Biotech, Inc.

      20.6.1. Company Overview

      20.6.2. Products And Services

      20.6.3. Business Strategy

      20.6.4. Financial Overview

      21. Key Mergers And Acquisitions In The Rituximab Biosimilars Market

      21.1. Innovent Biologics And Eli Lilly and Company Collaboration

      21.2. Teva Pharmaceuticals And Celltrion Healthcare Jointly Launched TRUXIMA

      21.3. Coherus Biosciences Acquired Rights From Innovent Biologics

      21.4. Ibio, Inc. Collaborated With CC-Pharming Ltd.

      21.5. Torrent Pharmaceuticals Collaborated with Reliance Life Sciences

      21.6. Forty Seven Inc. Collaborated With Acerta Pharma

      21.7. Sanofi Partnered with JHL Biotech

      22. Rituximab Biosimilars Market

      22.1. Global Rituximab Biosimilars Market In 2025 – Countries Offering Most New Opportunities

      22.2. Global Rituximab Biosimilars Market In 2025 – Segments Offering Most New Opportunities

      22.3. Global Rituximab Biosimilars Market In 2025 – Growth Strategies

      22.3.1. Market Trend Based Strategies

      22.3.2. Competitor Strategies

      23. Rituximab Biosimilars, Conclusions And Recommendations

      23.1. Conclusions

      23.2. Recommendations

      23.2.1. Product

      23.2.2. Place

      23.2.3. Price

      23.2.4. Promotion

      23.2.5. People

      24. Appendix

      24.1. Market Data Sources

      24.2. Research Methodology

      24.3. Currencies

      24.4. Research Inquiries

      24.5. The Business Research Company

      24.6. Copyright and Disclaimer

    List Of Tables

      Table 1: Global Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 2: Global Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 3: Global Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 4: Global Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 5: Global Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 6: Global Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 7: Global Rituximab Biosimilars Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 8: Global Rituximab Biosimilars Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 9: Global Rituximab Biosimilars Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 10: Global Rituximab Biosimilars Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 11:  Asia Pacific Population By Age Group, 2015-2025, Thousands
    • Table 12: Asia-Pacific Per Capita Healthcare Expenditure, 2015-2019, $
    • Table 13: Asia-Pacific Per Capita Net Disposable Income, 2015-2019, $
    • Table 14: Asia-Pacific Biologics Market Size, 2015-2025, $
    • Table 15: Asia-Pacific Prevalence Of Rheumatoid Arthritis, 2015-2019
    • Table 16: Asia-Pacific Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 17: Asia-Pacific Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 18: Asia-Pacific Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 19: Asia-Pacific Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 20:  China Population By Age Group, 2015-2025, Thousands
    • Table 21: China Per Capita Healthcare Expenditure, 2015-2019, $
    • Table 22: China Per Capita Net Disposable Income, 2015-2019, $
    • Table 23: China Biologics Market Size, 2015-2025, $
    • Table 24: China Prevalence Of Rheumatoid Arthritis, 2015-2019
    • Table 25: China Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 26: China Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 27: China Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 28: China Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 29:  India Population By Age Group, 2015-2025, Thousands
    • Table 30: India Per Capita Healthcare Expenditure, 2015-2019
    • Table 31: India Per Capita Net Disposable Income, 2015-2019, $
    • Table 32: India Biologics Market Size, 2015-2025, $
    • Table 33: India Prevalence Of Rheumatoid Arthritis, 2015-2019, $
    • Table 34: India Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 35: India Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 36: India Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 37: India Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 38:  Japan Population By Age Group, 2015-2025, Thousands
    • Table 39: Japan Per Capita Healthcare Expenditure, 2015-2019, $
    • Table 40: Japan Per Capita Net Disposable Income, 2015-2019, $
    • Table 41: Japan Biologics Market Size, 2015-2025, $
    • Table 42: Japan Prevalence Of Rheumatoid Arthritis, 2015-2019
    • Table 43: Japan Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 44: Japan Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 45: Japan Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 46: Japan Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 47: Australia Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 48: Australia Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 49: Australia Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 50: Australia Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 51: Indonesia Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 52: Indonesia Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 53: Indonesia Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 54: South Korea Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 55: South Korea Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 56: South Korea Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 57: South Korea Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 58:  Western Europe Population By Age Group, 2015-2025, Thousands
    • Table 59: Western Europe Per Capita Healthcare Expenditure, 2015-2019, $
    • Table 60: Western Europe Per Capita Net Disposable Income, 2015-2019, $
    • Table 61: Western Europe Biologics Market Size, 2015-2025, $
    • Table 62: Western Europe Prevalence Of Rheumatoid Arthritis, 2015-2019
    • Table 63: Western Europe Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 64: Western Europe Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 65: Western Europe Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 66: Western Europe Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 67:  UK Population By Age Group, 2015-2025, Thousands
    • Table 68: UK Per Capita Healthcare Expenditure, 2015-2019, $
    • Table 69: UK Per Capita Net Disposable Income, 2015-2019, $
    • Table 70: UK Biologics Market Size, 2015-2025, $
    • Table 71: UK Prevalence Of Rheumatoid Arthritis, 2015-2019
    • Table 72: UK Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 73: UK Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 74: UK Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 75: UK Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 76: Germany Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 77: Germany Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 78: Germany Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 79: Germany Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 80: France Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 81: France Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 82: France Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 83: France Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 84:  Eastern Europe Population By Age Group, 2015-2025, Thousands
    • Table 85: Eastern Europe Per Capita Healthcare Expenditure, 2015-2019, $
    • Table 86: Eastern Europe Per Capita Net Disposable Income, 2015-2019, $
    • Table 87: Eastern Europe Biologics Market Size, 2015-2025, $
    • Table 88: Eastern Europe Prevalence Of Rheumatoid Arthritis, 2015-2019
    • Table 89: Eastern Europe Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 90: Eastern Europe Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 91: Eastern Europe Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 92: Eastern Europe Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 93: Russia Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 94: Russia Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 95: Russia Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 96: Russia Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 97:  North America Population By Age Group, 2015-2025, Thousands
    • Table 98: North America Per Capita Healthcare Expenditure, 2015-2019, $
    • Table 99: North America Per Capita Net Disposable Income, 2015-2019, $
    • Table 100: North America Biologics Market Size, 2015-2025, $
    • Table 101: North America Prevalence Of Rheumatoid Arthritis, 2015-2019, $
    • Table 102: North America Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 103: North America Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 104: North America Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 105: North America Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 106:  USA Population By Age Group, 2015-2025, Thousands
    • Table 107: USA Per Capita Healthcare Expenditure, 2015-2019, $
    • Table 108: USA Per Capita Net Disposable Income, 2015-2019, $
    • Table 109: USA Biologics Market Size, 2015-2025, $
    • Table 110: USA Prevalence Of Rheumatoid Arthritis, 2015-2019, $
    • Table 111: USA Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 112: USA Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 113: USA Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 114: USA Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 115:  South America Population By Age Group, 2015-2025, Thousands
    • Table 116: South America Per Capita Healthcare Expenditure, 2015-2019, $
    • Table 117: South America Per Capita Net Disposable Income, 2015-2019, $
    • Table 118: South America Biologics Market Size, 2015-2025, $
    • Table 119: South America Prevalence Of Rheumatoid Arthritis, 2015-2019, $
    • Table 120: South America Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 121: South America Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 122: South America Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 123: South America Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 124: Brazil Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Table 125: Brazil Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 126: Brazil Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 127: Brazil Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 128:  Middle East Population By Age Group, 2015-2025, Thousands
    • Table 129: Middle East Per Capita Healthcare Expenditure, 2015-2019, $
    • Table 130: Middle East Per Capita Net Disposable Income, 2015-2019, $
    • Table 131: Middle East Biologics Market Size, 2015-2025, $
    • Table 132: Middle East Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 133: Middle East Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 134: Middle East Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 135:  Africa Population By Age Group, 2015-2025, Thousands
    • Table 136: Africa Per Capita Healthcare Expenditure, 2015-2019, $
    • Table 137: Africa Per Capita Net Disposable Income, 2015-2019, $
    • Table 138: Africa Biologics Market Size, 2015-2025, $
    • Table 139: Africa Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 140: Africa Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 141: Africa Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 142: Global Rituximab Biosimilars Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)
    • Table 143: Teva Pharmaceuticals – Financial Performance, 2015 – 2019, $ Billion
    • Table 144: Novartis AG – Financial Performance, 2016 - 2020, $ Billion
    • Table 145: Pfizer– Financial Performance, 2015 – 2019, $ Billion
    • Table 146: Shanghai Henlius Biotech, Inc. – Financial Performance, 2015 - 2019, $ Million
    • Table 147: Global Rituximab Biosimilars Market Size Gain ($ Million), 2020 – 2025, By Country
    • Table 148: Global Rituximab Biosimilars Market Size Gain ($ Million), Segmentation By Application, 2020 – 2025
    • Table 149: Global Rituximab Biosimilars Market Size Gain ($ Million), Segmentation By Distribution Channel, 2020 – 2025
    • Table 150: Rituximab Biosimilars- Market Data Sources

    List Of Figures

      Figure 1: Global Rituximab Biosimilars Market Segmentation By Application
    • Figure 2: Global Rituximab Biosimilars Market Segmentation By Distribution Channel
    • Figure 3: Global Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 4: Global Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 5: Global Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 6: Global Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 7: Global Rituximab Biosimilars Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 8: Global Rituximab Biosimilars Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 9: Asia-Pacific Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 10: Asia-Pacific Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 11: Asia-Pacific Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 12: China Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 13: China Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 14: China Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 15: India Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 16: India Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 17: India Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 18: Japan Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 19: Japan Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 20: Japan Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 21: Australia Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 22: Australia Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 23: Australia Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 24: Indonesia Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 25: Indonesia Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 26: South Korea Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 27: South Korea Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 28: South Korea Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 29: Western Europe Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 30: Western Europe Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 31: Western Europe Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 32: UK Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 33: UK Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 34: UK Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 35: Germany Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 36: Germany Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 37: Germany Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 38: France Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 39: France Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 40: France Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 41: Eastern Europe Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 42: Eastern Europe Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 43: Eastern Europe Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 44: Russia Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 45: Russia Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 46: Russia Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 47: North America Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 48: North America Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 49: North America Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 50: USA Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 51: USA Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 52: USA Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 53: South America Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 54: South America Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 55: South America Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 56: Brazil Rituximab Biosimilars Market, Historic, 2015 – 2020, $ Million
    • Figure 57: Brazil Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 58: Brazil Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 59: Middle East Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 60: Middle East Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 61: Africa Rituximab Biosimilars Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 62: Africa Rituximab Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 63: Global Rituximab Biosimilars Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)
    • Figure 64: Teva Pharmaceuticals – Financial Performance, 2015 – 2019, $ Billion
    • Figure 65: Novartis AG – Financial Performance, 2016 - 2020, $ Billion
    • Figure 66: Pfizer– Financial Performance, 2015 – 2019, $ Billion
    • Figure 67:  Shanghai Henlius Biotech, Inc. – Financial Performance, 2015 - 2019, $ Million
    Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
    Read More
    Global Gene Therapy Market 2022 – Market Opportunities And Strategies
    Read More
    The Microbiome Market Share, Market Size, And Growth Rate 2022
    Read More
    Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
    Read More
    The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
    Read More
    The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
    Read More
    The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
    Read More
    The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
    Read More
    Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies) By Delivery System (Liquid, Gel, Ointment) And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    Acne Drugs Market 2021 - By Type (Non-Inflammatory Acne Drugs, Inflammatory Acne Drugs), By End-User (Hospitals And Clinics), By Therapeutic Class (Benzoyl Peroxide, Retinoids, Antibiotics, Salicylice) And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    Cell And Gene Therapy Market 2021 - By Product (Cell Therapy, Gene Therapy), By Application (Oncology, Neurological Disorders) And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    HIV Drugs Market 2021 - By Type (Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs)) By Application (Hospital Pharmacies, Retail Pharmacies) By Administration (Oral, Parenteral) And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    Microbiome Market 2022 – By Type (Bacteria, Archaea, Viruses, Other Microbiomes), By Product (Therapeutics, Diagnostics), By Microbiome Therapeutic (Infectious Diseases, Gastrointestinal Disorders, Metabolic Disorders, Cancers, Others), By Microbiome Diagnostic (Genomics, Proteomics, Metabolomics), By End-Use (Infectious Diseases, Gastrointestinal Disorders, Metabolic Disorders, Cancers, Other Diseases), By Technology (Genomics, Proteomics, Metabolomics), And By Region, Opportunities And Strategies – Global Forecast To 2031
    View Report
    Pharmaceutical Drugs And Biologics Logistics Market 2021 - By Type Of Service (Cold Chain Logistics, Non-Cold Chain Logistics), By Mode Of Transport (Air Transportation, Ocean Transportation, Land Transportation), By Pharmaceutical Type (Pharmaceutical Drugs, Biologics), By Therapeutic Area (Metabolic Disorders Drugs, Anti-Infective Drugs, Central Nervous System Drugs, Respiratory Diseases Drugs, Cardiovascular Drugs, Musculoskeletal Disorders Drugs, Oncology Drugs, Hematology Drugs, Monoclonal Antibodies (MAbS), Genito-Urinary Drugs, Gastrointestinal Drugs, Therapeutic Proteins, Dermatology Drugs, Vaccines, Ophthalmology Drugs), And By Region, Opportunities And Strategies - Global Forecast To 2030
    View Report
    Antisense And RNAi Therapeutics Market 2021- By Technology (RNA Interference, Antisense RNA), By Route Of Administration (Intravenous injections, Intra Dermal injunctions, Other delivery methods), By Indication (Oncology, Cardiovascular device, Respiratory disorders, Neurological disorders, Infectious disease), And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report
    G-CSF (Granulocyte Colony Stimulating Factors) Market 2021 - By Type (Pegfilgrastim, Filgrastim, Lenograstim), By Application (Oncology, Blood Disorders, Chronic and Autoimmune Disorders), And By Region, Opportunities And Strategies – Global Forecast To 2030
    View Report